NASDAQ:YARW
Yarrow Bioscience, Inc.
Yarrow Bioscience, Inc.'s revenue grew 13.8% in fiscal 2025 to $570,000 while operating margin rose to −5219.1%. Free cash flow was −$33.1M, −5811.2% of revenue.Summary generated from Yarrow Bioscience, Inc.'s SEC filings. Latest annual report filed Feb 27, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$570,000
Revenue growth+13.8%
Revenue, 5-yr CAGR−51.4%
Gross marginn/a
Operating margin−5219.1%
Net margin−4646.1%
ROIC−130.9%
Return on equity−66.3%
Debt / equity0.00
Free cash flow−$33.1M
FCF margin−5811.2%
Share count change+0.4%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 | 0 | 0 | 1 | 1 |
| Operating income | −39 | −34 | −29 | −44 | −30 |
| Net income | −73 | −23 | −28 | −40 | −26 |
| Free cash flow | −56 | n/a | −25 | −34 | −33 |
Recent filings
- 8-KEntry into a material agreement
Sep 14, 2026 - 8-KOther events
Sep 10, 2026 - 8-K/AAmended results of operations and financial condition
Aug 13, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - 4Insider transaction report
Jul 30, 2026 - 8-KOther events
Jul 30, 2026 - 4Insider transaction report
Jul 29, 2026 - 8-KEntry into a material agreement
Jul 28, 2026